Fosun International Issues 1H2026 Positive Profit Alert as Core Industries Show Strong Resilience
Hengrui Pharma Wins First China Approval for Home-Grown Long-Acting Insulin Analog
Fosun expects 1H profit attributable to owners at RMB 1.5 billion-RMB 1.8 billion
From confidence to capital: Positioning biotech for the next growth cycle
Nomura Cuts HENGRUI PHARMA TP to HKD82.18, Lowers FY2026 Revenue and Profit Forecasts
Chinese biotech overtakes AI as emerging-market growth trade